Ganirelix vs Gonadorelin (GnRH)
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
The master hormone that controls your reproductive system and fertility
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Ganirelix
250–250 mcg
Gonadorelin (GnRH)
100–100 mcg
Frequency
Ganirelix
Once daily
Gonadorelin (GnRH)
Once daily
Administration
Ganirelix
Subcutaneous injection
Gonadorelin (GnRH)
Subcutaneous injection
Cycle length
Ganirelix
Ongoing/indefinite
Gonadorelin (GnRH)
Ongoing/indefinite
Onset speed
Ganirelix
Moderate (1-2 weeks)
Gonadorelin (GnRH)
Moderate (1-2 weeks)
Evidence level
Ganirelix
Strong human trials (Phase 3 or FDA approved)
Gonadorelin (GnRH)
Moderate human trials (Phase 1-2)
Benefit ratings
Ovulation Control
IVF Success Improvement
Safety & OHSS Prevention
Reproductive Health
Hormone Balance
Ovulation Support
Compound specifications
Ganirelix
Molecular formula
C80H113ClN18O13
Molecular weight
1570.4 g/mol
Half-life
10-12 hours
Bioavailability
~91% (subcutaneous injection)
CAS number
124904-93-4
Gonadorelin (GnRH)
Molecular formula
C55H75N17O13
Molecular weight
1182.3
Half-life
2-4 minutes
Bioavailability
Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)
CAS number
34973-08-5
Dosing compared
Ganirelix
Subcutaneous
250 mcg
Once daily during the mid-to-late follicular phase · Continued daily until the day of hCG administration (typically about 5-9 days)
FDA-labeled dose for inhibiting premature LH surges during controlled ovarian stimulation; started after several days of FSH and continued until hCG trigger [4].
Gonadorelin (GnRH)
Subcutaneous
100 mcg
Single dose · One-time diagnostic test
FDA-labeled gonadotropin (LH/FSH) stimulation test for pituitary reserve; 100 mcg given once subcutaneously (or IV), with LH measured at 0, 15, 30, 45, 60 and 120 minutes (Factrel) [4].
Intravenous
5 mcg per pulse (range 1-20 mcg)
Every 90 minutes via pulsatile pump · One or more ovulatory cycles; reassessed at 21-day intervals
FDA-labeled pulsatile regimen for ovulation induction in hypothalamic amenorrhea (Lutrepulse); intravenous pulsatile delivery gave better results than subcutaneous [5]. The 2-4 minute half-life makes pulsatile delivery essential.
Best suited for
Ganirelix
Improving IVF or ICSI success rates
Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature ovulation during egg retrieval cycles
Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Controlling ovarian stimulation in women with unpredictable cycles
Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gonadorelin (GnRH)
Improving fertility and conception chances
Gonadorelin (GnRH) is particularly well-suited for individuals focused on improving fertility and conception chances. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Regulating irregular menstrual cycles
Gonadorelin (GnRH) is particularly well-suited for individuals focused on regulating irregular menstrual cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing reproductive hormone levels
Gonadorelin (GnRH) is particularly well-suited for individuals focused on enhancing reproductive hormone levels. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting natural pregnancy attempts
Gonadorelin (GnRH) is particularly well-suited for individuals focused on supporting natural pregnancy attempts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Ganirelix
Common
- Mild discomfort at treatment site
- Injection site reactions (redness, bruising, swelling)
- Headaches
- Abdominal pain
- Pelvic discomfort
- Nausea
- Fatigue or dizziness
Serious
- Severe allergic reaction
Gonadorelin (GnRH)
Common
- Mild headache
- Local injection site reactions (redness, swelling)
- Temporary hot flashes
- Mood changes or emotional sensitivity
- Nausea or mild stomach upset
- Allergic skin reactions
- Dizziness or lightheadedness
- Temporary changes in vision
- Joint or muscle aches
- Insomnia or sleep disturbances
- Severe allergic reactions (difficulty breathing, swelling)
- Severe hormonal imbalance symptoms
- Ovarian hyperstimulation syndrome (OHSS)
- Signs of blood clots (chest pain, leg swelling)
- Severe mood changes or depression
Serious
- Severe allergic reaction
Safety & evidence
Ganirelix
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Ganirelix carries an excellent safety record from over 10,000 patients in FDA approval trials and 25+ years of clinical fertility practice. The antagonist mechanism avoids the flare effect seen with GnRH agonists, making it safer for women with diminished ovarian reserve. Injection site reactions are the most common issue (20-40% of patients), though typically mild bruising rather than systemic toxicity. The rapid 1-2 hour onset and quick clearance mean side effects resolve quickly if dosing is adjusted.
Contraindications
- Pregnancy or suspected pregnancy
- Breastfeeding
- Known allergies to any medication component
- Ovarian cysts larger than 3cm
Gonadorelin (GnRH)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
FDA approved for this use
Safety overview
Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.
Contraindications
- Pregnancy or breastfeeding
- Hormone-sensitive cancers (breast, prostate, ovarian)
- Severe pituitary or hypothalamic disease
- Undiagnosed abnormal vaginal bleeding
- Known hypersensitivity to GnRH
Which is right for you?
Choose Ganirelix if...
- Improving IVF or ICSI success rates
- Preventing premature ovulation during egg retrieval cycles
- Controlling ovarian stimulation in women with unpredictable cycles
Choose Gonadorelin (GnRH) if...
- Improving fertility and conception chances
- Regulating irregular menstrual cycles
- Enhancing reproductive hormone levels
- Supporting natural pregnancy attempts